Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric brain tumor consortium study PBTC-012

Journal of Clinical Oncology

Volumn 26, Issue 6, 2008, Pages 919-924

  MacDonald, Tobey J ^a   Stewart, Clinton F ^a   Kocak, Mehmet ^a   Goldman, Stewart ^a   Ellenbogen, Richard G ^a   Phillips, Peter ^a   Lafond, Deborah ^a   Poussaint, Tina Young ^a   Kieran, Mark W ^a   Boyett, James M ^a   Kun, Larry E ^a  

^a CHILDREN'S MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CILENGITIDE; ABCB1 PROTEIN, HUMAN; ANGIOGENESIS INHIBITOR; GLYCOPROTEIN P; SNAKE VENOM; UNCLASSIFIED DRUG;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLEEDING; BLOOD SAMPLING; BRAIN TUMOR; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; GLIOBLASTOMA; GRANULOCYTOPENIA; HUMAN; INTRATUMORAL HEMORRHAGE; LYMPHOCYTOPENIA; MALE; MAXIMUM TOLERATED DOSE; NEUROTOXICITY; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; URINALYSIS; ADOLESCENT; CHILD; CLINICAL TRIAL; DRUG ADMINISTRATION; GENETICS; GENOTYPE; INFANT; INTRAVENOUS DRUG ADMINISTRATION; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PRESCHOOL CHILD; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANGIOGENESIS INHIBITORS; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENOTYPE; HUMANS; INFANT; INFUSIONS, INTRAVENOUS; MAGNETIC RESONANCE IMAGING; MALE; P-GLYCOPROTEIN; SNAKE VENOMS; TREATMENT OUTCOME;

EID: 39749191543     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.14.1812     Document Type: Article

References (29)

1. Folkman J: Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29:15-18, 2002 (suppl 16)
2. Brooks PC, Montgomery AM, Rosenfeld M, et al: Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79:1157-1164, 1994
3. Friedlander M, Brooks PC, Shaffer RW, et al: Definition of two angiogenic pathways by distinct alpha v integrins. Science 270:1500-1502, 1995
4. Trikha M, Zhou Z, Timar J, et al: Multiple roles for platelet GPIIb/IIIa and alphavbeta3 integrins in tumor growth, angiogenesis, and metastasis. Cancer Res 62:2824-2833, 2002
5. Puduvalli VK, Sawaya R: Antiangiogenesis: Therapeutic strategies and clinical implications for brain tumors. J Neurooncol 50:189-200, 2000
6. Smith JW, Cheresh DA: Integrin (alpha v beta 3)-ligand interaction: Identification of a heterodimeric RGD binding site on the vitronectin receptor. J Biol Chem 265:2168-2172, 1990
7. Xiong JP, Stehle T, Zhang R, et al: Crystal structure of the extracellular segment of integrin alpha Vbeta3 in complex with an Arg-Gly-Asp ligand. Science 296:151-155, 2002
8. Westlin WF: Integrins as targets of angiogenesis inhibition. Cancer J 3:S139-S143, 2001 (suppl)
9. Dechantsreiter MA, Planker E, Matha B, et al: N-methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists. J Med Chem 42:3033-3040, 1999
10. Nicosia RF, Bonanno E: Inhibition of angiogenesis in vitro by Arg-Gly-Asp-containing synthetic peptide. Am J Pathol 138:829-833, 1991
11. Pfaff M, Tangemann K, Muller B, et al: Selective inhibition of cyclic RGD peptides of NMR defined conformation by alpha IIb beta 3, alpha V beta 3, and alpha 5 beta 1 integrins. J Biol Chem 269:20233-20238, 1994
12. Burke PA, DeNardo SJ, Miers LA, et al: Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res 62:4263-4272, 2002
13. MacDonald TJ, Taga T, Shimada H, et al: Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist. Neurosurgery 48:151-157, 2001
14. Hammes HP, Brownlee M, Jonczyk A, et al: Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. Nat Med 2:529-533, 1996
15. Lode HN, Moehler T, Xiang R, et al: Synergy between an antiangiogenic integrin alphav antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases. Proc Natl Acad Sci U S A 96:1591-1596, 1999
16. Taga T, Suzuki A, Gonzalez-Gomes I, et al: Alpha v-Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin. Int J Cancer 98:690-697, 2002
17. Mitjans F, Meyer T, Fittschen C, et al: In vivo therapy of malignant melanoma by means of antagonists of alphav integrins. Int J Cancer 87:716-723, 2000
18. Merck KGaA: EMD 121974 Investigator's Brochure. Darmstadt, Germany, Merck KGaA, 2006
19. Eskens F, Dumez H, Verweij J, et al: Phase I and pharmacologic study of cilengitide (EMD 121974), an alphavbeta3 and alphavbeta5 integrin inhibitor that perturbs tumor angiogenesis in patients with solid tumors. Proc Am Soc Clin Oncol 19:206a, 2000 (abstr 801)
20. Holden SN, Morrow M, O'Bryant C, et al: Correlative biological assays used to guide dose escalation in a phase I study of the antiangiogenic alphaVbeta3 and alphaVbeta5 integrin antagonist EMD 121974 (EMD). Proc Am Soc Clin Oncol 21:28a, 2002 (abstr 110)
21. Nabors LB, Mikkelsen T, Rosenfeld SS, et al: Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol 25:1651-1657, 2007
22. Goodman SN, Zahurak ML, Piantadosi S: Some practical improvements in the continual reassessment method for phase I studies. Stat Med 14:1149-1161, 1995
23. Pollack IF, Jakacki RI, Blaney SM, et al: Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: A Pediatric Brain Tumor Consortium report. Neuro Oncol 9:145-160, 2007
24. Kalbfleisch JD, Prentice RL: The Statistical Analysis of Failure Time Data. New York, NY, John Wiley, 1980, pp 163-188
25. Eskens FALM, Dumez H, Hoekstra R, et al: Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. Eur J Cancer 39:917-926, 2003
26. D'Argenio DZ, Schumitzky A: ADAPT II User's Guide. Los Angeles, CA, Biomedical Simulations Resource, University of Southern California, 1990
27. Zheng H, Webber S, Zeevi A, et al: The MDR1 polymorphisms at exons 21 and 26 predict steroid weaning in pediatric heart transplant patients. Hum Immunol 63:765-770, 2002
28. Zamber CP, Lamba JK, Yasuda K, et al: Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics 13:19-28, 2003
29. Chinn LW, Kroetz DL: ABCB1 pharmacogenetics: Progress, pitfalls, and promise. Clin Pharmacol Ther 81:265-269, 2007